CD38 and Miyoshi myopathy: Of particular concern is the subset of patients who are refractory to IMiDs, PIs, and anti-CD38 Abs, showing early relapse after first- or second-line therapy, including autologous stem cell transplantation (ASCT) or primary refractory MM patients.